<DOC>
	<DOC>NCT01087398</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and side effects of donor hematopoietic cells using chemotherapy regimen without total-body irradiation in children undergoing a hematopoietic stem cell transplant for Malignant infantile osteopetrosis. The blood stem cells will be derived from either related donor or unrelated umbilical cord blood or haploidentical donor.</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis</brief_title>
	<detailed_description />
	<mesh_term>Osteopetrosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Diagnosis of Osteopetrosis confirm by bone biopsy and radiographic imaging Age up to 5 year old Carbonic Anhydrase II (CAII) deficiency osteopetrosis variant Creatinine clearance ≤ 40ml/min/1.73m^2 or RTA Bilirubin ≥ 3mg/dL SGPT ≥ 500 U/L Current severe infection Evidence of CNS involvement Morbidity such as blindness or deafness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteopetrosis</keyword>
	<keyword>HSCT</keyword>
</DOC>